- Home
- ITRG vs BCAB Comparison
ITRG vs BCAB Comparison
Compare ITRG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- BCAB
- Stock Information
- Founded
- ITRG 1997
- BCAB 2007
- Country
- ITRG Canada
- BCAB United States
- Employees
- ITRG N/A
- BCAB N/A
- Industry
- ITRG Precious Metals
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ITRG Basic Materials
- BCAB Health Care
- Exchange
- ITRG Nasdaq
- BCAB Nasdaq
- Market Cap
- ITRG 277.2M
- BCAB 22.3M
- IPO Year
- ITRG N/A
- BCAB 2020
- Fundamental
- Price
- ITRG $1.50
- BCAB $0.38
- Analyst Decision
- ITRG Strong Buy
- BCAB Buy
- Analyst Count
- ITRG 1
- BCAB 2
- Target Price
- ITRG $2.75
- BCAB $1.00
- AVG Volume (30 Days)
- ITRG 1.3M
- BCAB 633.5K
- Earning Date
- ITRG 08-13-2025
- BCAB 08-07-2025
- Dividend Yield
- ITRG N/A
- BCAB N/A
- EPS Growth
- ITRG N/A
- BCAB N/A
- EPS
- ITRG N/A
- BCAB N/A
- Revenue
- ITRG $87,375,000.00
- BCAB $11,000,000.00
- Revenue This Year
- ITRG $746.16
- BCAB N/A
- Revenue Next Year
- ITRG N/A
- BCAB N/A
- P/E Ratio
- ITRG N/A
- BCAB N/A
- Revenue Growth
- ITRG N/A
- BCAB N/A
- 52 Week Low
- ITRG $0.79
- BCAB $0.24
- 52 Week High
- ITRG $1.95
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- ITRG 42.30
- BCAB 43.16
- Support Level
- ITRG $1.41
- BCAB $0.36
- Resistance Level
- ITRG $1.74
- BCAB $0.43
- Average True Range (ATR)
- ITRG 0.09
- BCAB 0.05
- MACD
- ITRG -0.02
- BCAB -0.01
- Stochastic Oscillator
- ITRG 27.27
- BCAB 11.48
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.